Sector News

Ipsen signs option to buy UCL spin-out Canbex

February 24, 2015
Life sciences
France’s Ipsen has bought an option to acquire the UK’s Canbex Therapeutics, which is working on a treatment for spasticity in people with multiple sclerosis.
 
Canbex is a spin-off of University College London that raised £2.3 million in 2013 from MS Ventures (the corporate venture arm of Merck KGaA), the Wellcome Trust and UCL Business. The therapy in question, called VSN16R, which has been shown in preclinical and Phase I studies to have the potential to provide substantially better patient care than existing systemic anti-spastic treatments, Ipsen says.
 
Ipsen has paid 6 million euros for the option to acquire Canbex at completion of a Phase IIa study. The latter’s present shareholders will be eligible to receive up to an additional 90 million euros, comprising an acquisition payment, plus royalties on VSN16R.
 
Ipsen chief executive Marc de Garidel said Canbex’ lead compound “has demonstrated excellent safety, efficacy and tolerability to date and fits well within our neurology franchise”. He added that “it could be a valuable companion product” to his company’s wrinkles and cervical dystonia treatment Dysport (abobotulinumtoxin A) in the treatment of spasticity.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.